Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 11, Issue 2, 1996, Pages 161-169

  Goldman, Anne I ^a   Carlin, Bradley P ^a   Crane, Lawrence R ^b   Launer, Cynthia ^a   Korvick, Joyce A ^c   Deyton, Lawrence ^d   Abrams, Donald I ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Didanosine; Surrogate marker; Zalcitabine; ZDV failure; ZDV intolerance

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; ZALCITABINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL MODEL; SURVIVAL RATE; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0030031884     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199602010-00007     Document Type: Article

References (19)

1. Phair J. Estimating prognosis in HIV-1 infection. Ann Intern Med 1993;118:741-2.
2. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. MMWR 1989;38(S-5):1-9.
3. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl Med 1990;322:941-9.
4. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327:581-7.
5. Byar DP, Schoenfield DA, Green SB, et al. Design considerations for AIDS trials. N Engl J Med 1990;323:1343-7.
6. Prentice RL Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40.
7. Yarchoan R, Venzon DJ, Pluda JM, et al. CD4 count and the risk of death in patients infected with HIV receiving antiret-roviral therapy. Ann Intern Med 1991;115:184-9.
8. Lin DY, Fischl MA, Schoenfeld DA. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. Stat Med 1993;12: 835-42.
9. + lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993;118:674-80.
10. Lagakos SW. Surrogate markers in AIDS clinical trials: conceptual basis, validation, and uncertainties. Clin Infect Dis 1993;16(suppl 1):S22-5.
11. Allan JD, DeGruttola V, Cross A, et al. An efficacy study of 2′3′-dideoxyinosine (ddI) (BMY-40900) administered orally twice daily to zidovudine intolerant patients with HIV infection (ACTG 118) [Abstract]. Presented at the Ninth Conference on AIDS, Berlin, Germany, 1993.
12. Fischl MA, Olson RM, Follansbee SE, Lalezari JP, Henry DH, Frame PT. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Intern Med 1993;118:762-9.
13. Abrams DI, Goldman AI, Launer C, et al. Comparative trial of didanosine and zalcitabine in patients with human immunodeficiency virus infection who are intolerant of or have failed zidovudine therapy. N Engl J Med 1994;330:657-62.
14. Laird NM, Ware JH. Random effects models for longitudinal data. Biometrics 1982;38:963-74.
15. Casella G, George EI. Explaining the Gibbs sampler. Am Stat 1992;46:167-74.
16. Lange N, Carlin BP, Gelfand A. Hierarchical Bayes models for the progression of HIV infection using longitudinal CD4 T-cell numbers. J Am Stat Assoc 1992;87:615-32.
17. Carlin BP, Poison NG. Monte Carlo Bayesian methods for discrete regression models and categorical time series. In: Bernardo JM, Berger JO, Dawid AP, Smith AFM, eds. Bayesian statistics 4, vol. 4. Oxford: Oxford University Press, 1992:577-86.
18. Albert JH, Chib S. Bayesian analysis of binary and polychotomous response data. J Am Stat Assoc 1993;88:669-79.
19. Little RJA, Rubin DB. Statistical analysis with missing data. New York: John Wiley and Sons, Inc., 1987.